Mineralocorticoid receptor blockade—a novel approach to fight hyperkalaemia in chronic kidney disease

Hyperkalaemia continues to be a major hazard of mineralocorticoid receptor blockade in an effort to retard the progression of chronic kidney disease (CKD). In cardiac patients on mineralocorticoid receptor blockade, RLY-5016 which captures K(+) in the colon has been effective in reducing the risk of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ritz, E., Pitt, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2013
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438399/
https://www.ncbi.nlm.nih.gov/pubmed/26120440
http://dx.doi.org/10.1093/ckj/sft084
Descripción
Sumario:Hyperkalaemia continues to be a major hazard of mineralocorticoid receptor blockade in an effort to retard the progression of chronic kidney disease (CKD). In cardiac patients on mineralocorticoid receptor blockade, RLY-5016 which captures K(+) in the colon has been effective in reducing the risk of hyperkalaemia. This compound might be useful in CKD as well.

Ejemplares similares